Evidence map›Paper›PMID 32110123›Full record

ArticlePsychology research and behavior management2020

The Effect of CoQ

Seyed Ahmad Hosseini, Nazanin Zahrooni, Ahmad Ahmadzadeh, Kambiz Ahmadiangali, Mohammad-Ali Assarehzadegan

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Psychology research and behavior management, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Seyed Ahmad HosseiniNutrition and Metabolic Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Nazanin ZahrooniDepartment of Nutrition, Faculty of Paramedicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Ahmad AhmadzadehThalassemia and Hemoglobinopathy Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Kambiz AhmadiangaliBiostatistics Division, Health School, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Mohammad-Ali AssarehzadeganImmunology Research Center, Institute of Immunology and Infectious Diseases, Iran University of Medical Science, Tehran, Iran.
Ahvaz Jundishapur University of Medical Sciences · IRIran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSurvival rates among breast cancer patients and the number of patients living with treatment side effects have improved, leading to increased focus on quality of life (QOL). The objective of this study was to determine the efficacy of CoQ

methodsThirty breast cancer patients were randomized into two groups. The first group received 100 mg CoQ

resultsThe data of 30 subjects were analyzed. According to QOL C30 data, CoQ

conclusionThis trial indicates that CoQ CLINICAL

trial registrationIRCT2015042021874N1.

Indexed as

breast cancerCoQ10quality of lifetamoxifen

Identifiers

PMID32110123
PMCPMC7039424
OpenAlexW3006734215

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.